Targeted drug-carrying filamentous phage nanomedicines

I. Yacoby*, H. Bar, L. Vax, I. Benhar

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

We present a novel application of filamentous bacteriophages as targeted drug carrying nanomedicines. The phages are engineered to display target-specificityconferring peptides or proteins on their coat, and carry a large payload of a cytotoxic drug that is conjugated to the phage major coat protein via a labile linker subject to controlled or delayed release. We show growth inhibition of target bacteria or cancer cells with impressive potentiation factors over the corresponding free drugs. We further show that targeted drug-carrying phages are non-toxic to mice and that their immunogenicity is reduced as a result of drug conjugation. Our approach replaces the selectivity of the drug itself with target selectivity born by the targeting moiety, which may allow the use and re-introduction of "non-specific" drugs that have thus far been excluded from antibacterial use (due to toxicity or low selectivity).

Original languageEnglish
Title of host publicationTechnical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, NSTI-Nanotech, Nanotechnology 2008
Pages438-441
Number of pages4
StatePublished - 2008
Event2008 NSTI Nanotechnology Conference and Trade Show, NSTI Nanotech 2008 Joint Meeting, Nanotechnology 2008 - Quebec City, QC, United States
Duration: 1 Jun 20085 Jun 2008

Publication series

NameTechnical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, NSTI-Nanotech, Nanotechnology 2008
Volume2

Conference

Conference2008 NSTI Nanotechnology Conference and Trade Show, NSTI Nanotech 2008 Joint Meeting, Nanotechnology 2008
Country/TerritoryUnited States
CityQuebec City, QC
Period1/06/085/06/08

Keywords

  • Antibiotic resistance
  • Immunogenicity
  • Phage nanomedicines
  • Targeted immunotherapy

Fingerprint

Dive into the research topics of 'Targeted drug-carrying filamentous phage nanomedicines'. Together they form a unique fingerprint.

Cite this